In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price ...

Alumis (ALMS) announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in ...

Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...

HC Wainwright reissued their buy rating on shares of Alumis (NASDAQ:ALMS – Free Report) in a report published on Monday,Benzinga reports. They currently have a $19.00 price objective on the stock. A ...

They’ve been a model of social housing since the Middle Ages but almshouses are suffering from the unintended consequences of ...

Acelyrin (NASDAQ:SLRN) announced Thursday a decision to adopt a limited-duration stockholder rights plan, also known as a poison pill, after Tang Capital Partners rapidly accumulated 8.8% of the ...

Friday marks three weeks since Pope Francis was hospitalized for bronchitis, which then led to double pneumonia.

Shares of Alumis Inc. (NASDAQ:ALMS – Get Free Report) have been given a consensus rating of “Buy” by the nine research firms that are covering the company, MarketBeat Ratings reports.

At the traffic junction at ITO in central Delhi, a girl in a torn frock weaves through the idling cars, tapping on windows ...

The death toll from Sunday’s tragic stampede at an alms-giving event in Bauchi State has risen to seven, police confirmed on ...

Lent gets its name from a word meaning “springtime,” the time of year when the hours of daylight are lengthening ...